Findings

What do systematic reviews say?

632 questions · 636 findings · 33 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 197 · 31%GRADE not reported 13 · 2%Very low 133 · 20.9%Low 159 · 25%Moderate 121 · 19%High 13 · 2%

BAL directed therapy vs usual care

FEV1 · infants and children with pulmonary exacerbations in cystic fibrosis

1 finding from 1 review

Bronchoscopy‐guided antimicrobial therapy for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 186 participants
Low

BAL directed therapy vs usual care

Z score FVC · infants and children with pulmonary exacerbations in cystic fibrosis

1 finding from 1 review

Bronchoscopy‐guided antimicrobial therapy for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Low

BAL directed therapy vs usual care

HRCT score · infants and children with pulmonary exacerbations in cystic fibrosis

1 finding from 1 review

Bronchoscopy‐guided antimicrobial therapy for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 181 participants
Moderate

BAL directed therapy vs usual care

Weight (z score) · infants and children with pulmonary exacerbations in cystic fibrosis

1 finding from 1 review

Bronchoscopy‐guided antimicrobial therapy for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 186 participants
Low

BAL directed therapy vs usual care

Number of positive P aeruginosa isolates · infants and children with pulmonary exacerbations in cystic fibrosis

1 finding from 1 review

Bronchoscopy‐guided antimicrobial therapy for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Low

BAL directed therapy vs usual care

Number or proportion of hospitalisations · infants and children with pulmonary exacerbations in cystic fibrosis

1 finding from 1 review

Bronchoscopy‐guided antimicrobial therapy for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Low

BAL directed therapy vs usual care

Hospital costs · infants and children with pulmonary exacerbations in cystic fibrosis

1 finding from 1 review

Bronchoscopy‐guided antimicrobial therapy for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Moderate

Laser therapy vs no laser therapy

Regression of PSR: change in number and size (in clock hours or in degrees of retinal circumference) of new blood vessels · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 247 participants
Very low

Laser therapy vs no laser therapy

Development of new PSR: proliferation of blood vessels at a new area/progression of existing PSR after treatment · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 247 participants
Very low

Laser therapy vs no laser therapy

Quality of life · children and adults with SCD and PSR

The review found no eligible studies for this question.

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Laser therapy vs no laser therapy

Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Very low

Laser therapy vs no laser therapy

Occurence of vitreous haemorrhage · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Low

Laser therapy vs no laser therapy

Adverse effects · children and adults with SCD and PSR

1 finding from 1 review

Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 414 participants
Low

Any prophylaxis vs on‐demand therapy with FEIBA

Overall bleeding rates: total number of bleeding events · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Any prophylaxis vs on‐demand therapy with FEIBA

Annualised bleeding rate · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Moderate

Any prophylaxis vs on‐demand therapy with FEIBA

Target joint bleeding rate · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Any prophylaxis vs on‐demand therapy with FEIBA

Annualized joint Bleeding Rate (AjBR) · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Moderate

Any prophylaxis vs on‐demand therapy with FEIBA

Quality of life · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 58 participants
Low

Any prophylaxis vs on‐demand therapy with FEIBA

Safety of bypassing agents · adults and children with hemophilia A or B with inhibitors

1 finding from 1 review

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 67 participants
Low

Amlodipine plus standard iron chelation therapy vs standard chelation therapy with or without placebo

Cardiac T2* value · or population: people with transfusion‐dependent beta thalassaemia

1 finding from 1 review

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion‐dependent beta… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 191 participants
Low